You are here
As experts in Preimplantation Genetic Diagnosis (PGD), Natera, formerly Gene Security Network (GSN), is dedicated to helping doctors give patients the best chance of having a healthy child.
Natera provides three separate and unique testing options:
- Preimplantation Genetic Diagnosis (PGD) for Aneuploidy: Using Natera's Proprietary Technology, Parental Support™, Natera provides three separate and unique testing options for pre-implantation embryos from an in vitro fertilization (IVF) cycle.
- Preimplantation Genetic Diagnosis (PGD) for Unbalanced Translocations and Inversions: Targeted chromosome testing with concurrent 24-chromosome aneuploidy screening for couples known to carry a balanced structural chromosome rearrangement.
- Preimplantation Genetic Diagnosis (PGD) for Single Gene Testing: Testing for one or more disease-linked genes in families with previously identified gene mutations at the same time that aneuploidy screening is performed.
The mission of Natera is to help fertility doctors give couples the best chance of having a healthy child. Natera was formed as Gene Security Network in 2004 by a team of doctors, geneticists, statisticians and software engineers who embarked on developing a technology, called Parental Support™, to enable highly reliable testing of multiple genes and chromosome copy number from a single cell. In 2012, Gene Security Network changed its name to Natera, a new name that better reflects the company's mission to help couples around the world manage pregnancies and reduce the risk of genetic disease.
Today, Natera's technology is being offered in Partner IVF Clinics for aneuploidy screening across all 24 chromosomes in time for Day 5 transfer. Testing of single gene disorders in parallel with aneuploidy screening is currently offered under a clinical study.
Natera has established relationships with the leading IVF Clinics and academic institutions across the United States.
Matthew Rabinowitz, Ph.D., CEO of Natera, is an authority in the field of Preimplantation Genetic Diagnosis (PGD) and informatics-based genetic testing. He has served as the Principal Investigator on six research grants awarded by the National Institutes of Health from which multiple publications have emerged in the leading journals of the field, such as em>Bioinformatics, Human Reproduction, and Molecular Human Reproduction. He actively presents at medical conferences around the world, including at the annual American Society of Reproductive Medicine (ASRM) meeting.
Dr. Rabinowitz has received the Scott Helt Memorial Award from IEEE and was selected by MIT Technology Review Magazine as one of the top 35 technology innovators under 35 in the United States. He joined the Stanford faculty in 2003, and is now a Consulting Associate Professor in Engineering.